Interview with Neuromod COO Diarmuid Flavin About the FDA Approval of Tinnitus Treatment Lenire

This episode features an interview with Diarmuid Flavin, Chief Operating Officer (COO) of Neuromod, a Dublin-based medical device company specializing in the treatment of tinnitus, a condition known as “ringing in the ears.” Tinnitus is believed to impact between 10 to 15 percent of adults worldwide.

The company recently received De Novo approval from the FDA for its tinnitus treatment Lenire. Lenire is the first of its kind, non-invasive, bimodal neuromodulation device that stimulates nerves to treat tinnitus. Diarmuid spoke about the approval and how Lenire helps address a significant unmet need in the tinnitus space.

Diarmuid brings more than 25 years of global leadership experience in a range of medical device, technology, and pharmaceutical companies to Neuromod, where he assumes responsibility for the company’s strategic operational execution, Regulatory Affairs, Engineering & Technology, Manufacturing Operations and Supply Chain teams.

Hear more about Lenire and Neuromod’s continuing work in biomodal neuromodulation technologies.

Read more here:

Lenire Bimodal Neuromodulation Device by Neuromod Improves Tinnitus Symptoms in Clinical Trial

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured